Repligen Reports Stronger-Than-Expected Q2 Results
Repligen Corporation (RGEN) reported second-quarter Non-GAAP earnings per share of $0.54, exceeding estimates by $0.09. Revenue came in at $204.1 million, a 11.9% year-over-year increase and surpassing expectations by $2.7 million. The company raised its full-year FY26 guidance for both organic revenue growth (now projected between 10.5%-13.5%) and adjusted EPS ($2.03-$2.09), which is above the consensus of $2.00. Following these results, Repligen's shares rose by approximately 5% in after-market trading. The strong performance reflects solid demand for its products across key markets, particularly within biopharmaceutical manufacturing and cell therapy solutions.
Tickers: $RGEN
Topics: Earnings Guidance Upgrade Revenue Beat